Business Wire

Cyemptive Technologies Announces Liaison Partnership with Netherlands-based Partnership for Cyber Security Innovation

9.7.2024 08:00:00 EEST | Business Wire | Press release

Share

Cyemptive Technologies, an award-winning provider of pre-emptive cybersecurity solutions for business and government, today announced that it has entered into a liaison partnership with Partnership for Cyber Security Innovation (PCSI) in the Netherlands.

PCSI is a public/private sector network of government bodies, research institutes, corporations and startups/scaleups and designed to make Dutch society more secure and resilient against future cyber-attacks. Its major partners include leading public and private sector organizations such as ABN Amro, Achmea, ASML, ING, Dutch Tax & Customs Administration and TNO.

“I am excited that Cyemptive joins the PCSI ecosystem as a Liaison Partner,” said Reinder Wolthuis, Program Manager PCSI. “PCSI is about innovation and collaboration. As a relatively young and innovative cybersecurity company and Cyemptive’s mission to transform the cybersecurity industry to a fully proactive approach, Cyemptive is a natural fit for PCSI.”

PCSI is an open innovation platform that aims to make Dutch society more secure and resilient against future cyber-attacks. By giving them a platform for sharing knowledge and expertise, PCSI offers its core partners a unique opportunity to develop innovative cybersecurity solutions that boost the cyber resilience of both individual companies and Dutch society in general. The innovation projects include a variety of cybersecurity challenges, from advanced detection systems to software for structuring data automatically and human-factor solutions.

“Being part of PCSI provides organizations with a platform to influence cybersecurity policies and standards,” said Rob Pike, founder and CEO of Cyemptive. “This ensures that their specific needs and concerns are considered in the development of industry regulations and guidelines.”

Cyemptive offers military-grade layers of pre-emptive cybersecurity protection that are essential add-ons for businesses to achieve cyber safety. Cyemptive’s ZeroStrike allows customers to be in command of their security by eliminating damage even from unknown attack vectors pre-zero day discovery. With Cyemptive ZeroStrike there is no need for recovery and remediation, an industry first capability.

About PCSI

Partnership for Cyber Security Innovation makes a vital contribution to a secure and resilient digital society through innovation in cybersecurity. Within PCSI, applicable, innovative cybersecurity solutions are developed that allow stakeholders in Dutch society to protect themselves against the cyber-attacks of tomorrow. By working together closely via an innovative ecosystem, PCSI partners connect applied research, current data and issues from society in the field of cybersecurity in a unique way.

About Cyemptive Technologies

Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 11 ‘ASTORS’ Homeland Security Awards from American Security Today in 2023 and received 10 awards in 2022 – more than any other company. Cyemptive’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240707748050/en/

Contacts

Belinda Young
BYPR
+1 206-932-3145
byoung@bypr.com

Rob Pike
Cyemptive Technologies
+1 425-341-9800
info@cyemptive.com

Wessel Graatsma
Vice President Cybersecurity Solutions Europe
+31 6 4868 2748
wgraatsma@cyemptive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye